Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Johnson & Johnson CEO and Chairman Joaquin Duato reported a series of transactions on August 13, 2026. He exercised 123,291 Employee Stock Options at an exercise price of $115.67 per share, receiving an equal number of common shares. On the same date he sold 20,976 shares at $262.00 per share and 102,315 shares at $261.00 per share. Indirect holdings reported include 1,018 shares held through a 401(k) plan and 30,852 shares held by his spouse, with the 401(k) amount including shares accrued via dividend reinvestment under the Johnson & Johnson Savings Plan.
Johnson & Johnson insider Joaquin Duato filed to sell up to 123,291 shares of common stock through Fidelity Brokerage Services on the NYSE, dated 08/13/2026. The shares were acquired via stock option exercise for cash and follow a prior sale of 48,480 shares on 08/05/2026 for an aggregate of $12,515,010.09.
Johnson & Johnson CEO and chairman Joaquin Duato reported selling 48,480 shares of common stock on August 5, 2026, in two open-market transactions at weighted average prices of $258.056 and $258.739. He continues to report indirect holdings of 1,018 shares via a 401k plan and 30,852 shares held by his spouse.
Johnson & Johnson executive Elizabeth Forminard, EVP and Chief Legal Officer, exercised employee stock options covering 9,344 shares of common stock on August 6, 2026. These options, granted under the company’s Long-Term Incentive Plan, had an exercise price of $131.94 per share and an expiration date of February 11, 2029.
On the same date, she acquired 9,344 shares of common stock through the option exercise and then sold a total of 15,918 shares of common stock in open market or private transactions, including 9,344 shares at $257.755 per share and 6,574 shares at $255.932 per share. After the exercise, the reported balance for this specific stock option award was 0 shares.
A shareholder of Johnson & Johnson (JNJ) filed a notice to sell common stock under Rule 144. The planned sale covers 15,918 shares of common stock with an aggregate market value of $4,090,957.06, to be sold on or after 08/06/2026 on the NYSE.
The shares derive from a stock option exercise of 9,344 shares dated 08/06/2026 and multiple restricted stock vesting events between 07/01/2022 and 02/14/2025, totaling 6,574 shares. The filing lists no securities sold during the past three months.
Johnson & Johnson, as an institutional investment manager, submitted a Form 13F Holdings Report covering its reportable equity positions. The summary shows 15 entries in the information table with an aggregate reported value of $798,650,757, rounded to the nearest dollar.
The report also identifies 1 other included manager, Johnson & Johnson Innovation - JJDC, Inc., indicating that this affiliate’s reportable holdings are consolidated under Johnson & Johnson for this Form 13F reporting period.
Johnson & Johnson submitted a Form 144 notice covering potential sales of its common stock through J.P. Morgan Securities LLC on the NYSE. The disclosure also lists issuer transactions in the past three months related to executive compensation, including 4,625 shares of common stock on 02/15/2026 and 43,855 shares on 02/13/2026.
Johnson & Johnson announced that Jennifer Taubert will retire as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee, effective September 1, 2026, after a career spanning more than 21 years with the company.
Under her leadership, the Innovative Medicine business grew to more than $60 billion in annual revenue. She will be succeeded by Tom Cavanaugh, currently Company Group Chairman, North America, Innovative Medicine, who will become Executive Vice President, Worldwide Chairman, Innovative Medicine and join the Executive Committee as part of a planned leadership transition.
Johnson & Johnson completed the acquisition of Firefly Bio, Inc., a biotechnology company with its proprietary Firelink™ degrader antibody conjugate platform, for $1 billion in cash. The deal is accounted for as an asset acquisition and will result in an in-process research and development charge of approximately $1 billion in the third quarter of 2026. Firefly is expected to dilute adjusted operational earnings per share and adjusted earnings per share by approximately $0.46 in 2026 and approximately $0.08 in 2027.
The company also entered strategic agreements and a collaboration with Sail Biomedicines, involving total initial payments of $785 million, including a $465 million equity investment, up to $140 million in contingent milestone payments, and an exclusive option to acquire Sail for $2.58 billion. Assuming exercise of the option, these agreements are expected to dilute adjusted operational EPS and adjusted EPS by approximately $0.18 in 2026 and approximately $1.28 in 2027. Together, the transactions reduce 2026 adjusted operational EPS guidance by about $0.64 to a range of $10.86–$11.01 (midpoint $10.94) and adjusted EPS to $10.96–$11.11 (midpoint $11.04), and shift adjusted pre-tax operating margin from an expected ~75 bps increase to a ~75 bps decrease versus the prior year, a combined impact of ~150 bps, while maintaining 2026 sales growth guidance.